NCT02402062 - A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 11, 2015

Primary Completion Date

May 31, 2018

Study Completion Date

January 10, 2020

Conditions

Neuroendocrine TumorsPancreatic Neoplasms

Interventions

DRUG

TH-302 + Sunitinib

"Combination of the two drugs in cycles of 28 days, described as follows:~Sunitinib: 37,5 mg/day Oral everyday of each 28 day cycle.~TH-302: 340 mg/m2 IV on days 8, 15 and 22 of each cycle."

Trial Locations (10)

18014

Hospital Universitario Virgen de las Nieves, Granada

28034

Hospital Universitario Ramón y Cajal, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

28046

Hospital Universitario La Paz, Madrid

29010

Hospital Universitario Virgen de la Victoria, Málaga

39008

Hospital Universitario Marqués de Valdecilla, Santander

41013

Hospital Universitario Virgen del Rocío, Seville

08907

Institut Catalá d'Oncologia L'Hospitalet, L'Hospitalet de Llobregat

Unknown

Hospital Provincial de Castellón, Castellon

08035

Hospital Universitari Vall d'Hebron, Barcelona